These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8462128)

  • 1. Oral bioavailability of mesna tablets.
    Stofer-Vogel B; Cerny T; Borner M; Lauterburg BH
    Cancer Chemother Pharmacol; 1993; 32(1):78-81. PubMed ID: 8462128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
    Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
    el-Yazigi A; Ernst P; al-Rawithi S; Legayada E; Raines DA
    J Clin Pharmacol; 1997 Jul; 37(7):618-24. PubMed ID: 9243355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
    James CA; Mant TG; Rogers HJ
    Br J Clin Pharmacol; 1987 May; 23(5):561-8. PubMed ID: 3109461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration].
    Roth B; Cerny T; Brunner KW; Küpfer A
    Schweiz Med Wochenschr; 1989 Aug; 119(34):1153-8. PubMed ID: 2510294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of orally administered mesna.
    Burkert H; Lücker PW; Wetzelsberger N; Breuel HP
    Arzneimittelforschung; 1984; 34(11):1597-600. PubMed ID: 6441581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.
    Shaw IC; Weeks MS
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):933-5. PubMed ID: 3117563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP; Epelman S; Bush DA
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
    Goren MP; Anthony LB; Hande KR; Johnson DH; Brade WP; Frazier MW; Bush DA; Li JT
    J Clin Oncol; 1998 Feb; 16(2):616-21. PubMed ID: 9469350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.
    Jones MS; Murrell RD; Shaw IC
    Eur J Cancer Clin Oncol; 1985 May; 21(5):553-5. PubMed ID: 3924627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of sodium 2-mercaptoethanesulfonate (MESNA) and its metabolite, disulfide form (DIMESNA), in volunteers after oral dosing: a comparison between MESNA and ARGIMESNA.
    Pea F; Mazzo M; Miglioli PA; Casiglia E; Pessina A; Moretti V
    Pharmacol Res; 1992; 25 Suppl 1():85-6. PubMed ID: 1508821
    [No Abstract]   [Full Text] [Related]  

  • 13. Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna.
    el-Yazigi A; Yusuf A; al-Rawithi S
    Ther Drug Monit; 1995 Apr; 17(2):153-8. PubMed ID: 7624904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of circulating cyst(e)ine by oral and intravenous mesna.
    Stofer-Vogel B; Cerny T; Küpfer A; Junker E; Lauterburg BH
    Br J Cancer; 1993 Sep; 68(3):590-3. PubMed ID: 8353049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral administration of mesna with ifosfamide.
    Goren MP
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
    Verschraagen M; Zwiers TH; de Koning PE; Welink J; van der Vijgh WJ
    J Chromatogr B Biomed Sci Appl; 2001 Apr; 753(2):293-302. PubMed ID: 11334343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS].
    Xia T; Liu DD; Shi LF; Hu JH
    Yao Xue Xue Bao; 2011 Aug; 46(8):951-4. PubMed ID: 22007521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.